Projections of cancer prevalence by phase of care: A potential tool for planning future health service needs

Journal of Cancer Survivorship

Volumn 7, Issue 4, 2013, Pages 641-651

  Yu, Xue Qin ^a,b   Clements, Mark ^c   O'Connell, Dianne ^a,b,d,e  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cancer prevalence; Epidemiology; Health service planning; Phase of care; Statistical projection; Survivorship

Indexed keywords

ARTICLE; FEMALE; FORECASTING; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH SERVICE; HUMAN; INCIDENCE; MALE; METHODOLOGY; NEOPLASM; PATIENT CARE; PREVALENCE; RECURRENT DISEASE; STATISTICS; SURVIVAL RATE; SURVIVOR; THEORETICAL MODEL;

CONTINUITY OF PATIENT CARE; DELIVERY OF HEALTH CARE; FEMALE; FORECASTING; HEALTH PLANNING; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INCIDENCE; MALE; MODELS, THEORETICAL; NEOPLASMS; PREVALENCE; RECURRENCE; SURVIVAL RATE; SURVIVORS;

EID: 84888294459     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-013-0303-9     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61: 69-90.
2. Mariotto AB, Yabroff KR, Feuer EJ, De Angelis R, Brown M. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control. 2006;17: 1215-26.
3. Capocaccia R, Colonna M, Corazziari I, et al. Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol. 2002;13: 831-9.
4. Gatta G, Capocaccia R, Berrino F, Ruzza MR, Contiero P. Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Ann Oncol. 2004;15: 1136-42.
5. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends and multiple primary cancer analyses from the surveillance, epidemiology and end results (SEER) programme. Oncologist. 2007;12: 20-37.
6. Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin. 2009;59: 264-73.
7. Scheer A, Auer RA. Surveillance after curative resection of colorectal cancer. Clin Colonrectal Surg. 2009;22: 242-50.
8. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365: 1687-717.
9. Yabroff KR, Warren JL, Schrag D, et al. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care. 2009;47: S56-63.
10. Fritz A, Percy C, Jack A, et al., editors. International classification of diseases for oncology. 3rd ed. Geneva, Switzerland: World Health Organisation; 2000.
11. Armstrong K, O'Connell DL, Leong D, Spigelman A, Armstrong BK. The New South Wales colorectal cancer care survey-Part 1 surgical management. Sydney: Cancer Council New South Wales; 2004.
12. Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 2002;21: 3511-26.
13. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6: 101-21.
14. Verdecchia A, De Angelis R, Capocaccia R, et al. The cure for colon cancer: results from the EUROCARE study. Int J Cancer. 1998;77: 322-9.
15. Krogh V, Micheli A. Measure of cancer prevalence with a computerised programme: an example on larynx cancer. Tumori. 1996;82: 287-90.
16. Gail MH, Kessler L, Midthune D, Scoppa S. Two approaches for estimating disease prevalence from population-based registries of incidence and total mortality. Biometrics. 1999;55: 1137-44.
17. Chauvenet M, Lepage C, Jooste V, Cottet V, Faivre J, Bouvier AM. Prevalence of patients with colorectal cancer requiring follow-up or active treatment. Eur J Cancer. 2009;45: 1460-5.
18. Mariotto A, Warren JL, Knopf KB, Feuer EJ. The prevalence of patients with colorectal carcinoma under care in the US. Cancer. 2003;98: 1253-61.
19. Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021. BJU Int. 2011;108: 1734-8.
20. Shulman LN, Jacobs LA, Greenfield S, et al. Cancer care and cancer survivorship care in the United States: will we be able to care for these patients in the future? J Oncol Pract. 2009;5: 119-23.
21. Baili P, Hoekstra-Weebers J, van Hoof E, et al. Cancer rehabilitation indicators for Europe. Eur J Cancer. 2013;49: 1356-64.
22. Baili P, Vicentini M, Tumino R, et al. A method for differentiating cancer prevalence according to health status, exemplified using a population-based sample of Italian colorectal cancer cases. Acta Oncol. 2013;52: 294-302.
23. Maddams J, Utley M, Moller H. Levels of acute health service use among cancer survivors in the United Kingdom. Eur J Cancer. 2011;47: 2211-20.
24. Warren JL, Mariotto AB, Meekins A, Topor M, Brown ML. Current and future utilisation of services from medical oncologists. J Clin Oncol. 2008;26: 3242-7.
25. Erikson C, Salsberg E, Forte G, Bruinooge S, Goldstein M. Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Pract. 2007;3: 79-86.
26. Scott IA. Health care workforce crisis in Australia: too few or too disabled? Med J Aust. 2009;190: 689-92.
27. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50: 1783-99.
28. Cluze C, Delafosse P, Seigneurin A, Colonna M. Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study. Eur J Cancer Prev. 2009;18: 343-8.
29. O'Connell MJ, Campbell ME, Goldberg RM, et al. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008;26: 2336-41.
30. Rodriguez-Moranta F, Salo J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomised, controlled trial. J Clin Oncol. 2006;24: 386-93.
31. Clements MS, Roder DM, Yu XQ, Egger S, O'Connell DL. Estimating prevalence of distant metastatic breast cancer: a means of filling a data gap. Cancer Causes Control. 2012;23: 1625-34.
32. Young JM, Leong DC, Armstrong K, et al. Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study. Med J Aust. 2007;186: 292-5.
33. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007;16: 566-71.
34. Maher EJ, Makin W. Life after cancer treatment-a spectrum of chronic survivorship conditions. Clin Oncol (R Coll Radiol). 2007;19: 743-5.
35. Levit L, Smith AP, Benz EJ, Ferrell B. Ensuring quality cancer care through the oncology workforce. J Oncol Pract. 2010;6: 7-11.
36. Lambert PC. Modelling of the cure fraction in survival studies. Stata J. 2007;7: 351-75.